
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience Inc has achieved significant advancements in its clinical-stage assets, particularly with ALTO-207, which is noted for its improved tolerability compared to pramipexole, allowing for higher doses and faster titration in treating depressive symptoms. The company's financial performance reflects this progress, as ALTO-207 generated $1.08 billion in revenue for FY24, marking a substantial 60% increase from FY23. Additionally, the development of a new transdermal formulation for ALTO-101, which has shown an enhanced safety profile and promising pharmacokinetics, further supports the positive outlook on the effectiveness of Alto's precision psychiatry pipeline.
Bears say
Alto Neuroscience Inc has experienced significant stock pressure since its initial public offering in 2024, primarily due to the failure of its lead asset, ALTO-100, in a crucial Phase 2b study for major depressive disorder. The failure not only undermined confidence in the company's core strategy but also raised concerns regarding the efficacy of its ongoing programs, including a Phase 2b study in bipolar depression, which is characterized by a low probability of success. Furthermore, the company's focus on neurobiology and biomarkers, while innovative, has faced challenges given the complexities of deficits in neuroplasticity that can exacerbate treatment resistance and negative outcomes in patients, significantly impacting its overall investment appeal.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares